Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry)
- PMID: 26316618
- DOI: 10.1161/CIRCULATIONAHA.115.015677
Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry)
Abstract
Background: Prospective data on the safety and efficacy of the wearable cardioverter defibrillator (WCD) in a real-world setting are lacking. The Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II) Registry was designed to provide real-world data on the WCD as a strategy during a period of risk stratification.
Methods and results: The WEARIT-II Registry enrolled 2000 patients with ischemic (n=805, 40%), or nonischemic cardiomyopathy (n=927, 46%), or congenital/inherited heart disease (n=268) prescribed WCD between August 2011 and February 2014. Clinical data, arrhythmia events, implantable cardioverter defibrillator implantation, and improvement in ejection fraction were captured. The median age was 62 years; the median ejection fraction was 25%. The median WCD wear time was 90 days, with median daily use of 22.5 hours. There was a total of 120 sustained ventricular tachyarrhythmias in 41 patients, of whom 54% received appropriate WCD shock. Only 10 patients (0.5%) received inappropriate WCD therapy. The rate of sustained ventricular tachyarrhythmias by 3 months was 3% among patients with ischemic cardiomyopathy and congenital/inherited heart disease, and 1% among nonischemic patients (P=0.02). At the end of WCD use, 840 patients (42%) were implanted with an implantable cardioverter defibrillator. The most frequent reason not to implant an implantable cardioverter defibrillator following WCD use was improvement in ejection fraction.
Conclusions: The WEARIT-II Registry demonstrates a high rate of sustained ventricular tachyarrhythmias at 3 months in at-risk patients who are not eligible for an implantable cardioverter defibrillator, and suggests that the WCD can be safely used to protect patients during this period of risk assessment.
Keywords: death, sudden, cardiac; defibrillator, implantable; defibrillators; tachycardia, ventricular.
© 2015 American Heart Association, Inc.
Comment in
-
Arrhythmias: Results from the WEARIT-II registry.Nat Rev Cardiol. 2015 Nov;12(11):621. doi: 10.1038/nrcardio.2015.143. Epub 2015 Sep 15. Nat Rev Cardiol. 2015. PMID: 26370478 No abstract available.
Similar articles
-
Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator.Heart Rhythm. 2018 Sep;15(9):1379-1386. doi: 10.1016/j.hrthm.2018.04.014. Epub 2018 Apr 18. Heart Rhythm. 2018. PMID: 29678779
-
One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry).Pacing Clin Electrophysiol. 2018 Oct;41(10):1307-1313. doi: 10.1111/pace.13448. Epub 2018 Jul 26. Pacing Clin Electrophysiol. 2018. PMID: 29992590
-
Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator.Heart Rhythm. 2021 Mar;18(3):404-410. doi: 10.1016/j.hrthm.2020.11.025. Epub 2020 Nov 26. Heart Rhythm. 2021. PMID: 33248269
-
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31. Eur Heart J. 2013. PMID: 23729691 Review.
-
Bridging a temporary high risk of sudden arrhythmic death. Experience with the wearable cardioverter defibrillator (WCD).Pacing Clin Electrophysiol. 2010 Mar;33(3):353-67. doi: 10.1111/j.1540-8159.2009.02590.x. Epub 2009 Nov 2. Pacing Clin Electrophysiol. 2010. PMID: 19889186 Review.
Cited by
-
Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death.Herzschrittmacherther Elektrophysiol. 2022 Mar;33(1):55-62. doi: 10.1007/s00399-021-00816-w. Epub 2021 Oct 25. Herzschrittmacherther Elektrophysiol. 2022. PMID: 34694459 English.
-
Sex differences in achieving guideline-recommended heart rate control among a large sample of patients at risk for sudden cardiac arrest.Heart Rhythm O2. 2024 Apr 15;5(5):274-280. doi: 10.1016/j.hroo.2024.04.008. eCollection 2024 May. Heart Rhythm O2. 2024. PMID: 38840767 Free PMC article.
-
Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure.Heart Fail Rev. 2016 Jul;21(4):433-46. doi: 10.1007/s10741-016-9542-y. Heart Fail Rev. 2016. PMID: 26910804 Review.
-
[Patients with a wearable cardioverter-defibrillator (WCD) : Prescription, function and rehabilitation support].Herz. 2019 Aug;44(5):379-389. doi: 10.1007/s00059-017-4650-6. Epub 2017 Dec 12. Herz. 2019. PMID: 29234842 Review. German.
-
Predictors of ventricular tachyarrhythmia in patients with a wearable cardioverter defibrillator: an international multicenter registry.J Interv Card Electrophysiol. 2024 Nov;67(8):1917-1928. doi: 10.1007/s10840-024-01869-w. Epub 2024 Jul 10. J Interv Card Electrophysiol. 2024. PMID: 38985244 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical